FDA Expands Inclusion Criteria For WorldHeart LVAS Destination Therapy Trial
This article was originally published in The Gray Sheet
Executive Summary
FDA has given conditional approval for WorldHeart to modify its pivotal trial of the Novacor implantable heart-assist pump. The changes are expected to accelerate the study, which has moved slowly since its start in 2004